InMed confirms INM-901 oral formulation for Alzheimer's; bioavailability comparable to injection

InMed Pharmaceuticals Inc.

Preclinical data show oral INM-901 achieves similar brain drug levels as intraperitoneal (IP) injection over 24h.
Oral delivery offers potential advantages over IV large-molecule antibody therapies, including lower cost and easier access.
INM-901 is a proprietary small molecule that crosses the blood-brain barrier via GI absorption.
Company conducting CMC, drug metabolism, dose-ranging, and PK studies to support IND submission.
Current disease-modifying Alzheimer's treatments require IV infusion every 2-4 weeks at medical facilities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.